Title: Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer
Authors: Sch√∂ffski, Patrick ×
Thate, B
Beutel, G
Bolte, O
Otto, D
Hofmann, M
Ganser, A
Jenner, A
Cheverton, P
Wanders, J
Oguma, T
Atsumi, R
Satomi, M #
Issue Date: Apr-2004
Publisher: Kluwer Academic Publishers
Series Title: Annals of Oncology vol:15 issue:4 pages:671-679
Abstract: Background: TZT-1027 is a synthetic dolastatin 10 analog with antineoplastic properties in various cell lines and tumor xenografts. The purpose of this phase I study was to evaluate the safety and toxicity, maximum tolerated dose, pharmacokinetics and pharmacodynamics, clinical and metabolic antitumor activity of TZT-1027 when given as a 1-h intravenous infusion every 3 weeks in patients with refractory solid tumors.
ISSN: 0923-7534
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Laboratory of Experimental Oncology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science